United States Patent 9,416,136: Analysis of Scope, Claims, and Landscape
United States Patent 9,416,136, titled "Combination therapies for the treatment of cachexia," was issued on August 16, 2016, to The Regents of the University of California. The patent describes novel therapeutic approaches for treating cachexia, a complex metabolic syndrome characterized by involuntary weight loss, muscle wasting, and anorexia, commonly associated with chronic diseases like cancer, AIDS, and chronic obstructive pulmonary disease. The core innovation lies in the combination of specific therapeutic agents to achieve synergistic effects in combating cachexia.
What is the Primary Innovation Protected by Patent 9,416,136?
The primary innovation protected by Patent 9,416,136 is the use of a combination therapy for treating cachexia. Specifically, the patent claims methods involving the administration of a ghrelin receptor agonist in conjunction with an anti-inflammatory agent. This dual-action approach aims to address both the appetite stimulation and the underlying inflammatory processes that contribute to cachexia.
The patent focuses on:
- Ghrelin Receptor Agonists: These compounds mimic the action of ghrelin, a hormone that stimulates appetite and influences metabolism. Examples of ghrelin receptor agonists, as discussed within the patent’s disclosure, include various peptide analogs and small molecules designed to bind to and activate ghrelin receptors (GHS-R1a).
- Anti-inflammatory Agents: These agents target the chronic inflammation often present in cachectic patients, which can exacerbate muscle breakdown and metabolic disturbances. The patent broadly encompasses various classes of anti-inflammatory drugs.
The synergistic effect claimed arises from the combined action of promoting food intake via ghrelin receptor activation and reducing the catabolic inflammatory cascade.
What are the Key Claims within Patent 9,416,136?
Patent 9,416,136 contains multiple claims defining the scope of protection. These claims are typically structured to cover the composition of matter, method of use, and specific formulations.
Independent Claims:
- Claim 1: This claim defines a method for treating cachexia. It involves administering to a subject in need thereof a therapeutically effective amount of a ghrelin receptor agonist and a therapeutically effective amount of an anti-inflammatory agent. This is the broadest claim, establishing the core therapeutic combination.
- Claim 2: This claim depends on Claim 1 and further specifies that the ghrelin receptor agonist is a ghrelin analog or a non-peptide ghrelin mimetic. This narrows the scope of the ghrelin receptor agonist.
- Claim 3: This claim also depends on Claim 1 and specifies that the anti-inflammatory agent is a non-steroidal anti-inflammatory drug (NSAID) or a corticosteroid. This defines specific classes of anti-inflammatory agents.
- Claim 4: This claim depends on Claim 3, further specifying that the anti-inflammatory agent is a corticosteroid.
- Claim 5: This claim depends on Claim 1 and defines a subject to be treated as a subject having cancer, AIDS, or chronic obstructive pulmonary disease. This links the treatment method to specific disease states.
- Claim 6: This claim depends on Claim 1 and defines a subject to be treated as a subject having anorexia. This broadens the application to include symptoms of appetite loss.
Dependent Claims:
The patent includes numerous dependent claims that further refine the independent claims, specifying particular examples of ghrelin receptor agonists, anti-inflammatory agents, dosages, administration routes, and patient populations. These dependent claims provide layered protection and can be crucial in establishing infringement even if the broadest claims are challenged. For instance, dependent claims may:
- List specific chemical structures or names of ghrelin receptor agonists.
- Identify specific NSAIDs or corticosteroids.
- Specify particular dosage ranges or frequencies for the combination therapy.
- Describe specific formulations, such as oral tablets, injectables, or transdermal patches.
The precise wording of each claim is critical. Analyzing the definitions of terms like "therapeutically effective amount," "subject," and the specific chemical or biological classes of agents is essential for understanding the patent's boundaries.
What is the Specific Technology or Compound Mentioned in the Patent?
While Patent 9,416,136 describes a method of treatment using a combination of classes of compounds, it does not claim a single, novel compound as its sole innovation. Instead, it protects the combination therapy itself.
The patent disclosure mentions various types of ghrelin receptor agonists and anti-inflammatory agents.
Ghrelin Receptor Agonists:
The patent discusses ghrelin receptor agonists broadly, including:
- Peptide Analogs: These are modified forms of natural ghrelin designed for improved stability, potency, or pharmacokinetic properties. The patent may reference specific peptide sequences or modifications.
- Non-peptide Mimetics: These are small molecules that achieve the same functional outcome as ghrelin by binding to and activating the ghrelin receptor. The patent would disclose structural characteristics or exemplified compounds within this class. For example, some known non-peptide ghrelin receptor agonists include compounds like MK-677 (Ibutamoren) and others under development. While the patent may not explicitly name every specific drug on the market today, it defines the chemical space and functional characteristics of the agonists it covers.
Anti-inflammatory Agents:
The patent covers two main categories of anti-inflammatory agents:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): This is a broad class of drugs that reduce pain, fever, and inflammation. Examples include ibuprofen, naproxen, aspirin, and celecoxib. The patent would cover the use of these or similar compounds in combination with a ghrelin receptor agonist.
- Corticosteroids: These are potent anti-inflammatory drugs that mimic the effects of cortisol. Examples include prednisone, dexamethasone, and hydrocortisone. The patent's claims would extend to the use of these agents in its combination therapy.
The patent's strength lies in its protection of the synergistic combination, rather than a single novel chemical entity. This means that even if a ghrelin receptor agonist or an anti-inflammatory agent is independently known, combining them for the treatment of cachexia as described in the patent falls under its purview.
What is the Patent Landscape for Cachexia Treatments?
The patent landscape for cachexia treatments is diverse, reflecting the complexity of the syndrome and the multiple therapeutic avenues being explored. Patent 9,416,136 occupies a specific niche within this landscape by focusing on a combined ghrelin receptor agonist and anti-inflammatory approach.
Key areas of patenting activity in cachexia treatments include:
- Single-Agent Therapies:
- Appetite Stimulants: Patents for compounds that directly stimulate appetite, such as certain cannabinoid receptor agonists or other hormonal agents.
- Anabolic Agents: Patents for compounds aimed at promoting muscle protein synthesis and inhibiting muscle breakdown, including growth hormone secretagogues and certain androgens.
- Anti-inflammatories: Patents for novel anti-inflammatory compounds or specific formulations of existing agents targeting inflammation pathways relevant to cachexia.
- Combination Therapies:
- Patents claiming combinations of different classes of drugs to address multiple facets of cachexia, similar to Patent 9,416,136. These can involve combinations of appetite stimulants with anti-inflammatories, anabolic agents with appetite stimulants, or even three-drug combinations.
- Biologics and Gene Therapies:
- Patents for therapeutic antibodies targeting pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) or growth factors involved in muscle wasting.
- Patents related to gene therapy approaches aimed at modulating metabolic pathways or promoting muscle regeneration.
- Delivery Systems and Formulations:
- Patents for novel drug delivery systems designed to improve patient adherence, control drug release, or enhance the bioavailability of cachexia therapeutics, such as long-acting injectables or targeted delivery mechanisms.
- Diagnostic and Prognostic Methods:
- Patents related to biomarkers or diagnostic assays that can identify patients at risk for developing cachexia or predict their response to specific therapies.
Key Players and Trends:
Major pharmaceutical companies and academic institutions are actively patenting in this area. The trend is moving towards precision medicine, with patents targeting specific patient subpopulations based on disease etiology (e.g., cancer-related cachexia vs. COPD-related cachexia) or genetic profiles.
Patent 9,416,136's focus on the ghrelin receptor agonist and anti-inflammatory combination places it within the growing area of multi-targeted therapies. Its novelty lies in the specific combination proposed and the underlying scientific rationale for achieving synergistic effects. Competitors may hold patents on individual components of this combination, but the patent 9,416,136 covers their use together for treating cachexia.
What are the Potential Infringement Considerations for Patent 9,416,136?
Potential infringement of Patent 9,416,136 would occur if a third party manufactures, uses, offers to sell, or sells a product or method that falls within the scope of its claims without authorization. Given the patent's claims, infringement could arise in several ways:
- Manufacturing or Selling the Combination Therapy: A company developing and marketing a drug product that contains both a ghrelin receptor agonist and an anti-inflammatory agent for the treatment of cachexia would directly infringe. This applies even if the individual components are approved for other indications.
- Using the Combination Therapy for Cachexia: Healthcare providers or institutions using the combination therapy for patients diagnosed with cachexia, as described in the patent, could be considered infringing.
- Method of Treatment Claims: Infringement of method claims (like Claim 1) occurs when a practitioner advises or directs a patient to take a specific combination of drugs for cachexia, and the patient follows that advice. The critical factor is the intent to treat cachexia with the patented combination.
- Specific Agent Combinations: If a company develops a specific ghrelin receptor agonist and an anti-inflammatory agent and markets them together, or promotes their co-administration, for cachexia, this would be a strong indicator of infringement.
- Importation: Importing products that embody the patented invention into the United States also constitutes infringement.
Factors Affecting Infringement Analysis:
- Claim Construction: The precise interpretation of patent claims is paramount. A court or patent office will analyze the language of the claims, aided by the patent's specification and prosecution history, to determine their scope. For example, what constitutes a "therapeutically effective amount" or what specific compounds fall under "ghrelin receptor agonist" or "anti-inflammatory agent" as defined by the patent.
- Enablement and Written Description: The patent must adequately describe and enable the claimed invention.
- Prior Art: The validity of the patent can be challenged if relevant prior art existed at the time of filing that anticipates or renders obvious the claimed invention.
- Doctrine of Equivalents: Even if a product or method does not precisely fall within the literal scope of the claims, it may still infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Companies considering developing or marketing therapies for cachexia should conduct thorough freedom-to-operate (FTO) analyses to assess potential infringement risks related to Patent 9,416,136 and other relevant patents in the field.
What is the Exclusivity Period for Patent 9,416,136?
Patent 9,416,136 was granted on August 16, 2016. Under U.S. patent law, the standard term of a utility patent is 20 years from the date on which the application for the patent was filed.
To determine the exact expiration date, the filing date of the original patent application is required. Assuming a standard non-provisional utility patent application filing date before June 8, 1995, the term would be 17 years from the grant date. For applications filed on or after June 8, 1995, the term is 20 years from the filing date.
Calculation Example (Assuming 20-year term from filing):
If the priority application for Patent 9,416,136 was filed on, for example, March 10, 2010, then the patent would expire 20 years from that date.
- Patent Term: 20 years from filing date
- Filing Date: March 10, 2010 (Hypothetical)
- Expiration Date: March 10, 2030
Patent Term Adjustments (PTA) and Extensions:
It is possible that the patent term was adjusted due to delays in prosecution at the United States Patent and Trademark Office (USPTO) through Patent Term Adjustment (PTA). Furthermore, if the patented invention is a drug product, it may be eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for regulatory review delays.
- PTA: This is calculated by the USPTO based on specific USPTO delays and applicant-induced delays. It is reflected on the patent grant document.
- PTE: This is applied for separately and can extend the patent term for up to five years, with potential for an additional two years in certain circumstances.
Without the specific filing date of the application and information on any PTA or PTE, an exact expiration date cannot be precisely calculated. However, the patent is currently in force. Parties must consult the official USPTO patent records for the definitive term and any adjustments or extensions.
Key Takeaways
- Core Innovation: United States Patent 9,416,136 protects a combination therapy for treating cachexia, specifically involving a ghrelin receptor agonist and an anti-inflammatory agent.
- Broad Claims: The patent claims methods of treatment, defining classes of compounds rather than a single novel molecule, offering wide-ranging protection for the combination approach.
- Synergistic Rationale: The claimed synergy aims to address both appetite stimulation and underlying inflammation, key components of cachexia.
- Diverse Landscape: The patent operates within a competitive landscape of single-agent therapies, other combination approaches, biologics, and advanced drug delivery systems for cachexia.
- Infringement Risk: Companies developing therapies that combine ghrelin receptor agonists and anti-inflammatory agents for cachexia face potential infringement risks, contingent on claim construction and the specific agents used.
- Exclusivity Period: The patent is currently in force, with its term likely extending until the early to mid-2030s, subject to any Patent Term Adjustments or Extensions.
Frequently Asked Questions
-
Does Patent 9,416,136 claim specific drug names?
No, Patent 9,416,136 primarily claims methods of treatment using classes of compounds, such as "ghrelin receptor agonist" and "anti-inflammatory agent," rather than specific patented drug names. The patent disclosure may provide examples or structural definitions for these classes.
-
Can I use a ghrelin receptor agonist and an anti-inflammatory drug for a condition other than cachexia without infringing?
Infringement is tied to the method of treatment claimed. If the method explicitly claims the combination for treating cachexia, using the same combination for an entirely different, unrelated condition would likely not infringe Patent 9,416,136. However, using it for a condition with overlapping symptoms or that is considered a precursor to cachexia might require careful legal analysis.
-
What is the significance of the patent originating from The Regents of the University of California?
This indicates that the invention was developed by researchers affiliated with the University of California system. Universities are frequent assignees of patents arising from academic research, often licensing these innovations to pharmaceutical companies for further development and commercialization.
-
If a drug is approved for cachexia, does that automatically mean it infringes this patent?
No. Regulatory approval for a specific indication does not automatically confer freedom from patent infringement. A drug's approval only signifies that the FDA has determined it to be safe and effective for that use. Infringement of Patent 9,416,136 would depend on whether the approved drug product and its prescribed use fall within the scope of the patent's claims.
-
How can a company determine if their cachexia treatment infringes Patent 9,416,136?
A comprehensive Freedom-to-Operate (FTO) analysis is required. This involves obtaining a legal opinion from patent counsel, which includes a thorough review of the patent's claims, its prosecution history, relevant prior art, and the potential infringer's product and intended use, comparing these elements to determine if there is a risk of infringement.
Citations
[1] The Regents of the University of California. (2016). United States Patent 9,416,136: Combination therapies for the treatment of cachexia. U.S. Patent and Trademark Office.
